110 related articles for article (PubMed ID: 37342338)
1. Immunohistochemical scoring of LAG-3 in conjunction with CD8 in the tumor microenvironment predicts response to immunotherapy in hepatocellular carcinoma.
Cheung CCL; Seah YHJ; Fang J; Orpilla NHC; Lau MC; Lim CJ; Lim X; Lee JNLW; Lim JCT; Lim S; Cheng Q; Toh HC; Choo SP; Lee SY; Lee JJX; Liu J; Lim TKH; Tai D; Yeong J
Front Immunol; 2023; 14():1150985. PubMed ID: 37342338
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy-induced recruitment of myeloid-derived suppressor cells abrogates efficacy of immune checkpoint blockade.
Kwong TT; Wong CH; Zhou JY; Cheng ASL; Sung JJY; Chan AWH; Chan SL
JHEP Rep; 2021 Apr; 3(2):100224. PubMed ID: 33604533
[TBL] [Abstract][Full Text] [Related]
3. Progenitor-like exhausted SPRY1
Liu Z; Zhang Y; Ma N; Yang Y; Ma Y; Wang F; Wang Y; Wei J; Chen H; Tartarone A; Velotta JB; Dayyani F; Gabriel E; Wakefield CJ; Kidane B; Carbonelli C; Long L; Liu Z; Su J; Li Z
Cancer Cell; 2023 Nov; 41(11):1852-1870.e9. PubMed ID: 37832554
[TBL] [Abstract][Full Text] [Related]
4. Intratumoral dendritic cell-CD4
Magen A; Hamon P; Fiaschi N; Soong BY; Park MD; Mattiuz R; Humblin E; Troncoso L; D'souza D; Dawson T; Kim J; Hamel S; Buckup M; Chang C; Tabachnikova A; Schwartz H; Malissen N; Lavin Y; Soares-Schanoski A; Giotti B; Hegde S; Ioannou G; Gonzalez-Kozlova E; Hennequin C; Le Berichel J; Zhao Z; Ward SC; Fiel I; Kou B; Dobosz M; Li L; Adler C; Ni M; Wei Y; Wang W; Atwal GS; Kundu K; Cygan KJ; Tsankov AM; Rahman A; Price C; Fernandez N; He J; Gupta NT; Kim-Schulze S; Gnjatic S; Kenigsberg E; Deering RP; Schwartz M; Marron TU; Thurston G; Kamphorst AO; Merad M
Nat Med; 2023 Jun; 29(6):1389-1399. PubMed ID: 37322116
[TBL] [Abstract][Full Text] [Related]
5. A modified immune cell infiltration score achieves ideal stratification for CD8
Pan B; Luo Y; Ye D; Qiu J; Zhang X; Wu X; Yao Y; Wang X; Tang N
Cancer Immunol Immunother; 2023 Dec; 72(12):4103-4119. PubMed ID: 37755466
[TBL] [Abstract][Full Text] [Related]
6. Inhibiting PLA2G7 reverses the immunosuppressive function of intratumoral macrophages and augments immunotherapy response in hepatocellular carcinoma.
Zhang F; Liu W; Meng F; Jiang Q; Tang W; Liu Z; Lin X; Xue R; Zhang S; Dong L
J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38272562
[TBL] [Abstract][Full Text] [Related]
7. Associations among the mutational landscape, immune microenvironment, and prognosis in Chinese patients with hepatocellular carcinoma.
Hu ZQ; Xin HY; Luo CB; Li J; Zhou ZJ; Zou JX; Zhou SL
Cancer Immunol Immunother; 2021 Feb; 70(2):377-389. PubMed ID: 32761426
[TBL] [Abstract][Full Text] [Related]
8. Tumor-Derived IL33 Promotes Tissue-Resident CD8
Chen L; Sun R; Xu J; Zhai W; Zhang D; Yang M; Yue C; Chen Y; Li S; Turnquist H; Jiang J; Lu B
Cancer Immunol Res; 2020 Nov; 8(11):1381-1392. PubMed ID: 32917659
[TBL] [Abstract][Full Text] [Related]
9. A high interferon gamma signature of CD8
Li S; Li K; Tian F; Li H; Xia Q; Li T; Dong B; Li D; Yu J; Zhang J; Wang L; Zhang C; Xu S; Zhao Y; Liu Y
Front Immunol; 2022; 13():1056144. PubMed ID: 36685525
[TBL] [Abstract][Full Text] [Related]
10. Antitumour effect of the mitochondrial complex III inhibitor Atovaquone in combination with anti-PD-L1 therapy in mouse cancer models.
Rodriguez-Berriguete G; Puliyadi R; Machado N; Barberis A; Prevo R; McLaughlin M; Buffa FM; Harrington KJ; Higgins GS
Cell Death Dis; 2024 Jan; 15(1):32. PubMed ID: 38212297
[TBL] [Abstract][Full Text] [Related]
11. Immunological Mechanisms behind Anti-PD-1/PD-L1 Immune Checkpoint Blockade: Intratumoral Reinvigoration or Systemic Induction?
Guo Z; Yu J; Chen Z; Chen S; Wang L
Biomedicines; 2024 Mar; 12(4):. PubMed ID: 38672120
[TBL] [Abstract][Full Text] [Related]
12. Identification of biomarkers of immune checkpoint blockade efficacy in recurrent or refractory solid tumor malignancies.
Yang RK; Qing Y; Jelloul FZ; Routbort MJ; Wang P; Shaw K; Zhang J; Lee J; Medeiros LJ; Kopetz S; Tetzlaff MT; Broaddus RR
Oncotarget; 2020 Feb; 11(6):600-618. PubMed ID: 32110280
[TBL] [Abstract][Full Text] [Related]
13. Comment on "An Injectable Hydrogel to Modulate T Cells for Cancer Immunotherapy".
Lin L; Zhang S; Yang W
Small; 2024 May; 20(18):e2302812. PubMed ID: 38072801
[TBL] [Abstract][Full Text] [Related]
14. Transcriptome deconvolution reveals absence of cancer cell expression signature in immune checkpoint blockade response.
Guo YA; Kulshrestha T; Chang MM; Kassam I; Revkov E; Rizzetto S; Tan AC; Tan DSW; Tan IB; Skanderup AJ
Cancer Res Commun; 2024 May; ():. PubMed ID: 38722600
[TBL] [Abstract][Full Text] [Related]
15. The GPCR-Gα
Wu VH; Yung BS; Faraji F; Saddawi-Konefka R; Wang Z; Wenzel AT; Song MJ; Pagadala MS; Clubb LM; Chiou J; Sinha S; Matic M; Raimondi F; Hoang TS; Berdeaux R; Vignali DAA; Iglesias-Bartolome R; Carter H; Ruppin E; Mesirov JP; Gutkind JS
Nat Immunol; 2023 Aug; 24(8):1318-1330. PubMed ID: 37308665
[TBL] [Abstract][Full Text] [Related]
16. Rationale of Immunotherapy in Hepatocellular Carcinoma and Its Potential Biomarkers.
Tai D; Choo SP; Chew V
Cancers (Basel); 2019 Dec; 11(12):. PubMed ID: 31816940
[TBL] [Abstract][Full Text] [Related]
17. Immune dysfunction signatures predict outcomes and define checkpoint blockade-unresponsive microenvironments in acute myeloid leukemia.
Rutella S; Vadakekolathu J; Mazziotta F; Reeder S; Yau TO; Mukhopadhyay R; Dickins B; Altmann H; Kramer M; Knaus HA; Blazar BR; Radojcic V; Zeidner JF; Arruda A; Wang B; Abbas HA; Minden MD; Tasian SK; Bornhäuser M; Gojo I; Luznik L
J Clin Invest; 2022 Nov; 132(21):. PubMed ID: 36099049
[TBL] [Abstract][Full Text] [Related]
18. WISP1 is associated to advanced disease, EMT and an inflamed tumor microenvironment in multiple solid tumors.
Gaudreau PO; Clairefond S; Class CA; Boulay PL; Chrobak P; Allard B; Azzi F; Pommey S; Do KA; Saad F; Trudel D; Young M; Stagg J
Oncoimmunology; 2019; 8(5):e1581545. PubMed ID: 31069142
[No Abstract] [Full Text] [Related]
19. Analyses of tumor microenvironment in patients with advanced renal cell carcinoma receiving immunotherapy (Meet-URO 18 study).
Catalano F; Brunelli M; Signori A; Rescigno P; Buti S; Galli L; Spada M; Masini C; Galuppini F; Vellone VG; Gaggero G; Maruzzo M; Merler S; Vignani F; Cavo A; Bimbatti D; Milella M; Dei Tos AP; Sbaraglia M; Murianni V; Damassi A; Cremante M; Maffezzoli M; Llaja Obispo MA; Banna GL; Fornarini G; Rebuzzi SE
Future Oncol; 2024 Apr; ():. PubMed ID: 38682738
[No Abstract] [Full Text] [Related]
20. A spatial architecture-embedding HLA signature to predict clinical response to immunotherapy in renal cell carcinoma.
Kinget L; Naulaerts S; Govaerts J; Vanmeerbeek I; Sprooten J; Laureano RS; Dubroja N; Shankar G; Bosisio FM; Roussel E; Verbiest A; Finotello F; Ausserhofer M; Lambrechts D; Boeckx B; Wozniak A; Boon L; Kerkhofs J; Zucman-Rossi J; Albersen M; Baldewijns M; Beuselinck B; Garg AD
Nat Med; 2024 May; ():. PubMed ID: 38773341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
